Neuromuscular

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

The chief medical advisor for the Muscular Dystrophy Association discussed the organization’s recent annual telethon and the efforts to inform the public about these diseases.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the role insurance companies play within the system for approving neurological devices for rare diseases.

Rozanolixizumab was associated with reductions in anti-acetylcholine receptor autoantibodies and was well tolerated across 2 dose levels with no new safety findings.

Here's what is coming soon to NeurologyLive.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

Seelos Therapeutics will soon enroll patients in its phase 2b/3 trial of SLS-005 in amyotrophic lateral sclerosis.

The professor of neurology at the NYU Langone Grossman School of Medicine detailed the ways the COVID-19 pandemic impacted mental health of frontline clinicians.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

A University of Miami Miller School of Medicine neuroscientist and molecular biologist is leading a collaborative study that could develop new insights into how cellular processes affect neurodegenerative diseases.

Researchers from the Mayo Clinic found a molecular target that can help assess potential treatments for spinocerebellar ataxia type 3, a disease which currently has no cure.

Evidence from 2 clinical trials were the basis of the biologics license application, with an FDA decision expected to be made by May 18, 2021.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 20, 2020.

After the 12-month open-label period, those treated with patisiran from the phase 3 APOLLO and phase 2 open-label parent studies maintained their improvements on the modified Neuropathy Impairment Score +7.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.

Sharon Hesterlee, PhD, the executive vice president and chief research officer at MDA spoke to the benefits of its new partnership with DNAnexus.

Here's what is coming soon to NeurologyLive.

The executive VP and chief research officer of MDA also discussed future plans on making MOVR and its platform accessible to centers outside of the MDA network.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 13, 2020.

COVID-19 positive patients with Guillain-Barre syndrome were predominately of demyelinating subtype and appeared more severe than non-COVID-19 patients with Guillain-Barré syndrome.

The executive VP and chief research officer of MDA spoke about how the new visualization reporting platform will also allow for easy recruitment of data to be used in future clinical trials and research studies.

The professor of neurology at the NYU Langone Grossman School of Medicine outlined the confusion on whether deaths are related to COVID-19, a symptom associated, or previously unidentified underlying condition.

New recommendations were developed for the use of rituximab, eculizumab, and methotrexate, as well as updates on previous recommendations for thymectomy.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

The professor of neurology at the NYU Langone Grossman School of Medicine gave her thoughts on how her recently published data on neurologic disorders in COVID-19 compare to previously reported data.

The 12-month results from the phase 2 TOPAZ clinical trial are anticipated by the second quarter of 2021, according to Scholar Rock.

Here's what is coming soon to NeurologyLive.